Peripheral Artery Disease

Digital Education Hubs

Return to Digital Educational Hub

CME Virtual Symposium

Cardiovascular Disease

Clinical Brief

Clinical Brief: Antithrombotic and Antiplatelet Therapy in the Cardiometabolic Patient

Get Started

CME/CE Credits: 1.0 hrs

Cardiovascular Disease

Virtual Symposium

Antithrombotic Therapy for Symptomatic PAD: Interpreting the Evidence and Recent Advances

Get Started

CME/CE Credits: 1.0 hrs

Cardiovascular Disease

Virtual Symposium

Preventing Adverse Cardiovascular and Limb Events in High-Risk Cardiometabolic Patients with Peripheral Artery Disease: Recent…

Get Started

CME/CE Credits: 1.0 hrs

News Digest

July 15, 2021 – In a new subgroup analysis of the COMPASS trial, the combination of low-dose rivaroxaban (2.5 mg twice/daily) and aspirin (100 mg once/daily) significantly reduced cardiovascular death compared to aspirin alone in patients with chronic CAD or PAD. Additionally, there were fewer deaths following MI, stroke, or cardiovascular procedures with the combination therapy, as well as fewer sudden cardiac, other, and unknown causes of CV deaths and coronary heart disease deaths. These mortality benefits were greater in patients with a higher baseline risk, supporting the results of the main study, which showed a greater benefit in patients with polyvascular disease, mild or moderate heart failure, chronic kidney disease, and diabetes. The results of this secondary analysis can better inform patient selection for dual pathway inhibition.

The full results of this study can be accessed here »

June 25, 2021 – In a new subgroup analysis of the VOYAGER-PAD trial presented at the 2021 American Diabetes Association (ADA) Scientific Sessions, authors reported that the benefits of rivaroxaban plus aspirin were consistent in PAD patients with critical limb ischemia (CLI) regardless of diabetes mellitus (DM) status. In this trial, 47% of CLI patients had comorbid DM, and the results of the analysis are important because the efficacy and safety of rivaroxaban in these patients was not established. However, because of baseline risk, the absolute benefit was greater in patients with both CLI and DM vs. those with CLI and without comorbid DM.

The full results of this analysis can be accessed here »

May 16, 2021 – The primary results of the VOYAGER-PAD trial showed that rivaroxaban 2.5mg twice daily plus aspirin, compared to placebo plus aspirin, reduced the risk of first events by about 15% in patients with peripheral artery disease (PAD) who underwent a lower extremity revascularization. The results of this secondary analysis of the VOYAGER-PAD trial showed that this approached also reduced the total event burden in these patients, including a 14% reduction in total primary events (included acute limb ischemia, major amputation of a vascular cause, nonfatal myocardial infarction, nonfatal ischemic stroke and cardiovascular death), and a 14% reduction in total vascular events (included peripheral revascularization and venous thromboembolic event). To watch Drs. Bhatt, Bonaca, and Patel discuss these results, please click here ».

The full results of this study can be accessed here »

Expert Highlights and Perspectives

Interview #1

Marc Bonaca, MD, one of the principal investigators of the VOYAGER-PAD trial, joins us to discuss new data presented at the 2021 American Diabetes Association (ADA) and the International Society on Thrombosis and Haemostasis (ISTH) meetings (recorded July 28, 2021).

Marc Bonaca,
MD

Watch Now

Interview #2

Watch Drs. Bhatt, Bonaca, and Patel recap the symposium at 2021 CMHC Spring, as well as discuss some recent data on antithrombotic therapy for PAD that were presented at 2021 American College of Cardiology meeting, including:

Deepak Bhatt,
MD

Marc Bonaca,
MD

Manesh Patel,
MD

The concept and the rationale of total (first and subsequent) events in PAD
Total vascular events in the VOYAGER-PAD trial: efficacy and safety
Implications of these recent sub-analyses
Dual antiplatelet therapy (DAPT) vs. dual platelet inhibition (DPI):
patient selection and strategies

Watch Now

Interview #3

Watch as experts Deepak Bhatt, MD, Marc Bonaca, MD, and Manesh Patel, MD, discuss additional clinical pearls from the 2020 CMHC Annual Meeting on the management of high-risk peripheral artery disease patients, including:

Deepak Bhatt,
MD

Marc Bonaca,
MD

Manesh Patel,
MD

Summary of the main results of the COMPASS and VOYAGER-PAD trials
Summary of sub-analyses of these trials
Take home points and practice implications

Watch Now

Peer-to-Peer Educational Toolkits

A compilation of key content from the Primetime Symposium at the 2020 15th Annual CMHC Live Online

Download Now

Peripheral Artery Disease

Digital Education Hubs

CME Virtual Symposium

News Digest

Expert Highlights and Perspectives

Marc Bonaca, MD, one of the principal investigators of the VOYAGER-PAD trial, joins us to discuss new data presented at the 2021 American Diabetes Association (ADA) and the International Society on Thrombosis and Haemostasis (ISTH) meetings (recorded July 28, 2021).

Watch Drs. Bhatt, Bonaca, and Patel recap the symposium at 2021 CMHC Spring, as well as discuss some recent data on antithrombotic therapy for PAD that were presented at 2021 American College of Cardiology meeting, including:

Watch as experts Deepak Bhatt, MD, Marc Bonaca, MD, and Manesh Patel, MD, discuss additional clinical pearls from the 2020 CMHC Annual Meeting on the management of high-risk peripheral artery disease patients, including:

Peer-to-Peer Educational Toolkits

A compilation of key content from the Primetime Symposium at the 2020 15th Annual CMHC Live Online

A compilation of key content from the Primetime Symposium at 2021 CMHC Spring

Subscribe to "The Monthly Beat" Newsletter

Quick Links

Professional Education

Connect

QUICK LINKS

Professional Education

Industry Resources

Subscribe